Gilead will present new data on virologic suppression in adults 65 years and older at AIDS 2020: Virtual this week.
Formulary Watch
Latest News
All News
Advertisement
Drug helps with heavily-treatment experienced (HTE) adults with multidrug-resistant HIV-1 infection.
Price of the drug to treat hospitalized patients revealed.
Colorectal cancer drug is the first immunotherapy administered as a first-line treatment and without chemotherapy.
These are the top 3 drugs recently approved — or soon to be approved by FDA — to watch in 2020.
Investigational treatment will target marginal zone lymphoma (MZL) and follicular lymphoma (FL).
The agency revoked its emergency use authorization (EUA) for the drug, while warning about a dangerous interaction with remdesivir.
The unique formulation is a dispersible tablet for children.
Five pharma markers are recalling the diabetes medication due to the presence of a carcinogenic ingredient.
HHS says supply could run out by the end of this month.
Advertisement
The agency welcomes another option for serious bacterial infections.
Brilinta is already approved to prevent atherothrombotic events in ASC.
Immediately after the FDA said it found elevated levels of the carcinogenic ingredient N-nitrosodimethylamine (NDMA) in certain extended release (ER) metformin products, the first 2 major recalls are underway.
IV artesunate is the only drug available in the U.S. to treat the disease.
FDA authorizes first stand-alone, at-home test, plus other top COVID-19 news stories.
Antigen tests, a new category, have a major advantage and disadvantage over COVID-19 tests already approved.
Numerous PPEs and testing kits also feature unproven coronavirus claims.
Formulation could cause fewer administration-related reactions than IV Darzalex.
Popular heartburn medication now in shortage due to COVID-19 test.
Agency says the anti-malaria drug can cause heart rhythm problems.
Suppliers claim CBD can help alleviate opioid addiction, cure diseases.
The drug, plus chemotherapy, shows a significant survival benefit.
Hospitals could receive $75 billion in funding to combat coronavirus.
Olumiant trial joins other RA drug trials, including hydroxychloroquine.
An NIH trial on the controversial anti-malaria medication is underway.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
National Alliance survey shows employers are leaving the ‘big 3’ for other PBMs
2
7 takeaways from the MHE webinar on PBM reform and transparency
3
Novo Nordisk's ziltivekimab falls short to reduce cardiovascular events in phase 3 trial
4
What employees may miss when they buy drugs directly online
5